Healthcare Services

Rising Hypertension Cases Fueling The Growth Of The Market Due To Increasing Risk Of Heart Attacks Is Supporting Development Across The Acute Myocardial Infarction Market

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Acute Myocardial Infarction Market By 2030?

The market size for acute myocardial infarction has shown robust growth over recent years. It is anticipated to expand from $1.56 billion in 2025 to $1.65 billion in 2026, with a compound annual growth rate (CAGR) of 6.0%. Historically, this expansion has been influenced by factors including the increasing prevalence of coronary artery disease, a rise in hospital and specialty cardiac centers, the widespread adoption of electrocardiogram and imaging techniques, heightened awareness of acute MI symptoms, and an increase in cardiac research initiatives.

The acute myocardial infarction market is projected to experience robust expansion in the coming years. Its valuation is anticipated to reach $2.06 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.7%. This projected growth can be ascribed to several factors, including the advancement of new thrombolytic agents, the increasing application of minimally invasive procedures, the integration of sophisticated imaging technologies, the evolution of personalized cardiology treatments, and the incorporation of AI and big data in cardiac care. Noteworthy trends expected during the forecast period involve the rising uptake of percutaneous coronary intervention (PCI) procedures, an increase in the utilization of advanced cardiac biomarkers for early detection, a concentrated effort on less invasive cardiac therapies, the broadening scope of telecardiology and remote patient monitoring, and enhanced public awareness and prevention initiatives for acute MI.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp

Which Growth Drivers Are Expected To Support The Acute Myocardial Infarction Market Forward?

The increasing instances of hypertension are anticipated to boost the growth of the acute myocardial infarction market moving forward. Hypertension is a medical condition marked by consistently elevated blood pressure, which elevates the risk of cardiac issues, strokes, and various other health complications. The number of hypertension cases is on the rise due to the growing occurrence of sedentary lifestyles, often resulting from desk-bound work, prolonged screen exposure, and minimal physical exercise. Hypertension contributes to acute myocardial infarction by causing damage to arteries, promoting the buildup of plaque, and increasing the probability of blood clots forming that can block coronary arteries. For instance, in September 2025, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that in 2024, approximately 1.4 billion adults globally, aged 30–79, were living with hypertension, accounting for about one-third of individuals in that age bracket. Consequently, the rising hypertension cases are driving the expansion of the acute myocardial infarction market.

How Is The Acute Myocardial Infarction Market Structured Across Different Market Segments?

The acute myocardial infarction market covered in this report is segmented –

1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)

2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications

3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan

4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route

5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes

Subsegments:

1) By ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)

2) By Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

What Trends Are Affecting The Growth Of The Acute Myocardial Infarction Market?

Major companies active in the acute myocardial infarction market are concentrating on securing regulatory approvals to expand their range of products, boost the effectiveness of treatments, and strengthen their market standing. Regulatory approvals are formal authorizations granted by health agencies such as the FDA and EMA, ensuring that drugs and medical devices meet necessary safety, efficacy, and quality standards before entering the market. For instance, in March 2025, Sungen Biomedical, a biopharmaceutical company based in China, obtained FDA Fast Track Designation for its monoclonal antibody drug, SGC001, which is the world’s first developed for the emergency treatment of acute myocardial infarction (AMI). This designation acknowledges SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic areas. With promising preclinical results indicating benefits in recovery and reduced mortality, Fast Track status enables expedited FDA communication, thereby accelerating the approval process and ensuring quicker patient access to this innovative AMI therapy.

Which Organizations Are Involved In The Acute Myocardial Infarction Market?

Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc

Access The Complete Acute Myocardial Infarction Market Report:

https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report

Which Region Is The Dominant Market In The Acute Myocardial Infarction Market?

North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acute Myocardial Infarction Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23291&type=smp

Browse Through More Reports Similar to the Global Acute Myocardial Infarction Market 2026, By The Business Research Company

Acute Coronary Syndrome Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Myocardial Ischemia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Coronary Artery Disease Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795